France · Delayed Price · Currency is EUR Valneva SE Earnings Call Transcripts
Fiscal Year 2026
-
A specialty vaccine company highlighted its strong commercial portfolio, robust R&D pipeline, and strategic focus on innovation. The Lyme disease vaccine, partnered with Pfizer, is a key near-term catalyst, with phase 3 data expected in H1 2026 and significant market potential.
Fiscal Year 2025
-
2025 revenues slightly exceeded prior year, driven by proprietary vaccine growth and disciplined cash management, despite reduced third-party sales. Key pipeline programs advanced, with pivotal Lyme vaccine data expected H1 2026 and Shigella phase II data mid-year.
-
Revenues grew 9% to €127M, with strong IXIARO sales and improved gross margins, but IXCHIQ U.S. suspension and currency headwinds impacted results. Debt refinancing enhanced flexibility, and the Lyme vaccine remains the key growth driver, with regulatory submissions planned for 2026.
-
The company is advancing a Lyme disease vaccine with Pfizer, targeting commercialization in late 2027 and regulatory submissions in mid-2026. Other highlights include ongoing global commercialization of its chikungunya vaccine, growth in Japanese encephalitis vaccine sales, and upcoming Shigella vaccine data.
-
H1 2025 saw strong revenue growth, improved gross margins, and a robust cash position, driven by increased product sales and outbreak response. Key pipeline programs advanced, with the Lyme vaccine on track for regulatory submission in 2026 and IXCHIQ restrictions lifted after safety review.
-
Pivotal Lyme vaccine data is expected by year-end, with regulatory submission and potential approval targeted for the following years. IXCHIQ faces temporary setbacks due to safety concerns, while Shigella and Zika vaccine programs advance with key data readouts anticipated soon.
-
Q1 2025 saw robust revenue growth, improved gross margins, and reduced cash burn, with strong IXIARO and DUKORAL sales and ramp-up of IXCHIQ. Regulatory progress and pipeline advances support a positive outlook, with guidance and profitability targets unchanged.
-
A specialty vaccine company presented its robust pipeline, highlighting a phase III Lyme disease vaccine with a major data readout expected by year-end, and strong commercial growth in travel and vector-borne disease vaccines. Financial guidance points to double-digit sales growth and a shift to proprietary products for improved margins.
Fiscal Year 2024
-
Achieved double-digit sales growth in 2024, with strong cash reserves and improved profitability driven by proprietary vaccines. Pipeline progress includes key clinical milestones for Lyme, Shigella, and Zika, with 2025 guidance forecasting further revenue growth and reduced cash burn.
-
A specialty vaccine developer highlighted its unique portfolio, including the only licensed chikungunya vaccine, an advanced Lyme vaccine in Phase III, and a leading Shigella program. Key 2025 catalysts include pivotal Lyme data, Shigella CHIM results, and a Zika Phase I readout.
-
Product sales grew 12% year-over-year to €112.5 million, with strong IXIARO and DUKORAL performance. Guidance for 2024 was narrowed, and the company remains on track for sustained profitability from 2027, driven by its Lyme vaccine program and a robust R&D pipeline.
-
Management outlined a strategy focused on unique vaccines for high unmet needs, with a fully integrated business model and a path to profitability driven by the Lyme vaccine launch. Key pipeline assets include VLA15 for Lyme, Ixchiq for chikungunya, and a quadrivalent Shigella vaccine, all with significant market opportunities and upcoming milestones.
-
Product sales grew 7% year-over-year (excluding COVID-19), led by IXIARO and the first IXCHIQ sales. Full-year guidance is reiterated, with strong R&D progress, new partnerships, and a solid cash position supporting future growth.
-
A strategic partnership was announced to accelerate development of a tetravalent Shigella vaccine, leveraging LimmaTech’s technology and Valneva’s commercial capabilities. The program targets significant unmet needs in both high-income and LMIC markets, with a risk-mitigated clinical plan and strong early data supporting its potential.